Source:Instrument Family

On March 28, the China Medical Equipment Conference and 2024 Medical Equipment Exhibition (CAME) officially opened in Chongqing. Medtronic, as the vice-chairman unit of the China Medical Equipment Association, has participated in the exhibition for three consecutive years, and this year it brought75 Innovative Products, coveringCardiovascular, Neuroscience, Medical SurgeryThree Major Business Areas.

It is worth mentioning that, while continuously leading technological innovation, Medtronic is alsoEmpower the Growth and Development of Local Medical Professionals, promote the upgrading of local medical service quality and the wide accessibility of high-quality medical care. Its on-site display showcasedMedtronic Innovation CenterUnder the spotlight.

In addition, during the exhibition, Medtronic focused onCardiac Rhythm Management and Cardiac Ablation SolutionsA thematic forum was held. The attending guests delivered brilliant keynote speeches and engaged in in-depth discussions on hot topics such as policy interpretation, clinical application, medical-engineering integration, and industry-university-research collaboration, focusing on the application and development of related products.

In 2024, it happens to beMedtronic Celebrates 75th Anniversary Worldwide, and at the same time, it is also the companyThe 35th Year of Investing in China. This year's China Medical Equipment Conference also kicked off the annual series of events for Medtronic to review its development history and look forward to an innovative future.

Medtronic Showcases 75 Innovative Products at This Year's Medical Equipment Exhibition, CoveringCardiac Rhythm Management, Cardiac Surgery, Cardiac Ablation, Structural Heart Disease, Orthopedics and Neurosurgery, ENT, and SurgeryAnd other businesses.

Medtronic, the inventor of the world's first battery-powered portable external cardiac pacemaker, has always been at the forefront of the industry in terms of technological iteration in cardiac pacemakers.Micra™ AV2 & VR2 Transcatheter Leadless Pacemaker System, which is the technical culmination of Medtronic's many years of deep cultivation in this field.

It is reported that,MicraHailed by media, including CCTV, as"The World's Smallest Heart Pacemaker", andMicra VR2 and Micra AV2 are the new generation of upgraded products.These two products were approved in the U.S. market in May 2023.

InMaintain the same volume and weightUnder the premise, Micra VR2 and Micra AV2 reduce chip power consumption and improve battery performance,Increased service life by 40%, while also featuring more intelligent algorithms, which are expected to achieve higher implant safety.

It is understood that the extension of battery life meansThe Micra leadless pacemaker can work continuously in the human body for up to nearly 17 years., reducing the need for pacemaker replacements and thereby lowering the overall treatment burden for patients with bradycardia.

Arctic Front Advance Pro™

Balloon Cryoablation Catheter

Currently, nearly 60 million people worldwide are deeply affected by atrial fibrillation (AF). AF management is a lifelong burden for patients, and antiarrhythmic drug therapy has always been the current standard first-line treatment. However, in patients receiving drug therapy, about half of those using antiarrhythmic drugs cannot fully control the occurrence of AF, and the side effects often caused by the frequent use of antiarrhythmic drugs may lead many to discontinue treatment.

MedtronicArctic Front Advance Pro Series Balloon Cryoablation Catheter, isCurrently the first and onlyApproved by NMPA for expanded indications through the indication expansion pathwayFirst-line Treatment for Paroxysmal Atrial Fibrillation and Treatment for Drug-refractory Persistent Atrial FibrillationThe ablation catheter has ushered in a new era of first-line treatment for atrial fibrillation catheter ablation in China. As a catheter specifically designed for PVI, it has laid the foundation for the innovation of atrial fibrillation ablation pulmonary vein isolation tools and the development of technology.

As of 2023, Medtronic's AFA series balloon cryoablation catheter in ChinaGlobal applications have exceeded 1.7 million cases, covering more than 100 countries and regions,Used in over 70,000 cases in China, which has been verified by millions of cases worldwide.

Avalus Artificial Heart Valve

Over the past 20 years, improvements in the long-term durability of cardiac bioprosthetic valves and the application of new transcatheter technologies to treat degenerated bioprosthetic valves have gradually increased the use of cardiac bioprosthetic valves. Ideally, a bioprosthetic heart valve should exhibit good hemodynamic stability, long-term durability, and ease of implantation.

January 18, 2022Medtronic Avalus Bovine Pericardial Bioprosthesis Officially Approved for Marketing by NMPA, this bioprosthetic valve isThe New Generation of Bovine Pericardial Aortic Valve Based on Medtronic's 40 Years of R&D Foundation, which has undergone brand disruptive and revolutionary innovation in structure and design, offering surgeons a completely new choice.

It is reported that Avalus, asThe World's First Zero-Metal Valve, patients are able to after implantationUnrestricted MRI Testing, andFully Prepared for Future TAVR Implantation, avoiding corrosion between metals. Meanwhile, the 5-year clinical follow-up data from the Perigon study shows that the AVALUS valve has excellentDurability and Safety。

Data shows that Medtronic'sHeli-FX™ EndoAnchor System, applicable toFixation and Sealing Between Endovascular Aortic Stent Graft and Autologous ArteryThe ESAR procedure had a one-year Type I endoleak rate of only 2.5% in the ANCHOR global multicenter, real-world study, with five-year follow-up data showing just 4.8%.

In addition, when the neck of an infrarenal abdominal aortic aneurysm (AAA) is too short, endosuture aneurysm repair (ESAR) can be used. The ESAR technique, which uses the Heli-FX™ EndoAnchor system in conjunction with the Endurant stent graft system, canSuitable for patients with aortic aneurysm neck lengths ranging from less than 10mm to 4mm, allowing more patients to benefit from endovascular interventional therapy.。

AiBLE™ Innovative Digital EcosystemIncludingIntegrated Solution for Digital and Intelligent OrthopedicsAndIntegrated Solution for Digital and Intelligent Neurosurgery. This innovative ecosystem organically integrates MedtronicGlobally Leading ImplantsAnd Mazor X spinal surgery navigation and positioning system / Stealth Autoguide cranial surgery positioning equipment, surgical navigation systems, surgical power systems, and other intelligent devices.

Based on an integrated platform, linked by big data and empowered by AI,Different treatment devices can achieve synergistic gains and full data exchange, leading the industry into a digital and intelligent era of whole-course disease management.While bringing globally leading orthopedic and neurosurgical innovative therapies to patients in China, it will also boost the digital and intelligent transformation of the industry, promoting high-quality development in these disciplines.

Medtronic Unveils at This ExhibitionSignia is an intelligent stapling system., Detecting tissue thickness through intelligent adaptive stapling technology, the OLED display provides real-time feedback of tissue information and actively adjusts the firing speed to assist the surgeon.Achieving Intelligent Control of Individualized Surgical Plans Based on Tissue Differences。

At the same time,Signia Adapts to the Full Series of Staple Cartridges Equipped with Intelligent Chips and Tri-Staple Technology, fully meeting clinical needs, achieving better accessibility, and bringing advanced intelligent stapling therapy to more patients.Signia and the Full Series of Smart StaplersAlreadyOfficially Approved by the National Medical Products Administration, realizing the transition from traditional mechanical anastomosis to intelligent anastomosis, empowering smart surgery.

In the field of otolaryngology, from the introduction of the first optical navigation system in 1998 to the present, otolaryngological surgical navigation systems have undergone more than two decades of development. From basic procedures to complex environments, MedtronicStealthStation ENT Navigation System for Otolaryngology SurgeryAll can provide support for ENT surgery, shorten operation time, and enhance the confidence of the surgeon.

From the perspective of a doctor's career growth, this system canSignificantly improve the learning efficiency of young doctors and shorten the learning curve.. The 3D modeling function of navigation can more intuitively explain the condition to patients, building a communication bridge between doctors and patients.

Data shows that this year marks the 75th anniversary of Medtronic's founding and also the 35th year of the company's investment in China. Currently, Medtronic has already establishedCovering R&D, production, sales, training, after-sales service, and investment fundsThe full value chain layout, which includes1 R&D Center, 2 Innovation Centers, and 5 Major Production Bases`, providing a solid foundation for the long-term localized development of enterprises.`

Medtronic Global Senior Vice President and Greater China President Gu Yushao stated: "This year marks the significant milestone of Medtronic's 75th anniversary globally and 35th anniversary of entering the Chinese market. As one of the first multinational medical technology companies to enter China,In the 35-year journey of Medtronic deeply integrating into the Chinese market, we have witnessed, participated in, and greatly benefited from the rapid development of China's healthcare industry.In the new era of opportunities, Medtronic strives to take on greater responsibility and mission.Actively introduce international resources to build a full value chain layout and an innovative ecosystem of internal and external collaboration in China."Strengthen exchanges and deepen cooperation with industry partners in R&D, manufacturing, venture capital, and clinical fields to continuously promote the high-quality development of the medical industry, benefiting more patients, more doctors, and more innovative forces."

In fact, during the 35 years of entering the Chinese market, Medtronic has witnessed, participated in, and benefited from the development of China's medical device market. To date, MedtronicHas Introduced More Than 700 Innovative Products to the Chinese Market, improve the treatment outcomes of locally prevalent diseases.

——

At present, China's medical device industry is developing at an astonishing speed. In the new era, the medical industry is ushering in an unprecedented transformation.

At the recently concluded "Two Sessions" in China, "new quality productive forces" emerged as a high-frequency buzzword across various industries. Characterized by high technology, high efficiency, and high quality, it provides strong driving energy for all sectors, including the medical industry.

In fact,The core of implementing new quality productive forces in the medical industry is to achieve industrial upgrading through technological innovation.Based on the development requirements of the industry chain, the starting point is to meet demands, drive innovation, and serve clinical needs and patients.

To this end, Medtronic continues to focus on local needs in China.Request, breaking through the product boundaries of "global use", and conducting "re-development" based on the needs of Chinese users.Medtronic stated that it hopes in the future toBased on the demand in the Chinese market，Combining the wisdom of Chinese doctors with the capabilities of Chinese entrepreneurs and developers,Develop more innovative, more advanced, and more suitable products for Chinese patients.

Related Reading

Tap for more!

$3.8 Billion Acquisition Makes Significant Progress

Powerful Collaboration: Samsung Focuses on AI Ultrasound

Minister of Commerce Meets with Global CEO of Medtronic: What Signal? How to Layout?

XLEAP-SBS Brings a Brand-New Upgrade to NextSeq™ 1000/2000

Giant in Debt of 269.5 Billion Makes a Move in Medical Devices

After $7.4 Billion Acquisition, Medtronic Officially Announces Split

Top 100 Hard-Core Technology Enterprises in Shanghai 2024: United Imaging, MicroPort, Aohua...

Medtronic's Lin Mao: Enhancing "Quality" with "Intelligence," Aiming to Become an "Insider" in China's Neurosurgery Market

Just now, Stryker announced the completion of a major acquisition.

$5.07 Billion Sale, Century-Old Giant Exits Medical Device Business

BusinessBusiness cooperation email: qxzj@landianyiliao.com